Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harald Hofer

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
BMC Infectious Diseases|January 8, 2017
The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver diseaseJim Young, Nina Weis, Harald Hofer, et al.
Journal of Hepatology|February 14, 2015
Hepatic steatosis in Wilson disease--Role of copper and PNPLA3 mutationsAlbert Friedrich Stättermayer, Stefan Traussnigg, Hans-Peter Dienes, et al.
Gastroenterology|November 14, 2009
Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic responsePeter Ferenci, Hermann Laferl, Thomas-Matthias Scherzer, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|May 21, 2016
DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation settingSandra Beinhardt, Ramona Al Zoairy, Peter Ferenci, et al.
Journal of Hepatology|June 1, 2016
Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertensionMattias Mandorfer, Karin Kozbial, Philipp Schwabl, et al.
Journal of Hepatology|April 22, 2015
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agentXavier Forns, Stuart C Gordon, Eli Zuckerman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 16, 2015
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGEMaria Buti, Stuart C Gordon, Eli Zuckerman, et al.
Wiener Klinische Wochenschrift|September 4, 2016
Indications for liver transplantation in adults : Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX)Ivo Graziadei, Heinz Zoller, Peter Fickert, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 24, 2010
Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis CAlbert Friedrich Stättermayer, Rudolf Stauber, Harald Hofer, et al.
Journal of Hepatology|July 16, 2013
A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infectionSandra Beinhardt, Berit Anna Payer, Christian Datz, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
BMC Infectious Diseases|January 8, 2017
The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver diseaseJim Young, Nina Weis, Harald Hofer, et al.
Journal of Hepatology|February 14, 2015
Hepatic steatosis in Wilson disease--Role of copper and PNPLA3 mutationsAlbert Friedrich Stättermayer, Stefan Traussnigg, Hans-Peter Dienes, et al.
Gastroenterology|November 14, 2009
Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic responsePeter Ferenci, Hermann Laferl, Thomas-Matthias Scherzer, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|May 21, 2016
DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation settingSandra Beinhardt, Ramona Al Zoairy, Peter Ferenci, et al.
Journal of Hepatology|June 1, 2016
Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertensionMattias Mandorfer, Karin Kozbial, Philipp Schwabl, et al.
Journal of Hepatology|April 22, 2015
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agentXavier Forns, Stuart C Gordon, Eli Zuckerman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 16, 2015
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGEMaria Buti, Stuart C Gordon, Eli Zuckerman, et al.
Wiener Klinische Wochenschrift|September 4, 2016
Indications for liver transplantation in adults : Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX)Ivo Graziadei, Heinz Zoller, Peter Fickert, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 24, 2010
Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis CAlbert Friedrich Stättermayer, Rudolf Stauber, Harald Hofer, et al.
Journal of Hepatology|July 16, 2013
A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infectionSandra Beinhardt, Berit Anna Payer, Christian Datz, et al.
Pageof 8